Results 81 to 90 of about 7,679 (193)

Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. [PDF]

, 2020
INTRODUCTION: Idiopathic chronic eosinophilic pneumonia (ICEP) is an orphan lung disease characterized by concomitant systemic and local eosinophilia, along with bilateral lung infiltrates.
Dahlqvist, Caroline, Pilette, Charles, Froidure, Antoine, Colinet, Benoît, Roufosse, Florence, Schleich, Florence Nicole Icole F., Brenard, Emeline, Schleich, Florence   +7 more
core   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

The effects of mepolizumab on sputum eosinophils (%). [PDF]

, 2013
The effects of mepolizumab on sputum eosinophils (%).
Yao Liu (173014), Shu-juan Jiang (395395), Song Zhang (180477), Dao-wei Li (395394)   +3 more
core   +1 more source

IL‐33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways

Allergy, EarlyView.
IL‐33 induces inflammatory gene signatures in eosinophils, characterised by the upregulation of cell surface markers, inflammatory mediators and regulatory factors, all of which were also observed in nasal polyp‐derived eosinophils. Ox‐LDL and complement fragments (C3a and C5a) promote eosinophil adhesion and survival.
Emiko Matsuyama, Jun Miyata, Takao Mochimaru, Ryuta Onozato, Yo Otsu, Hisashi Sasaki, Keeya Sunata, Shinichi Okuzumi, Katsunori Masaki, Hiroki Kabata, Keinosuke Hizuka, Yoshinori Hasegawa, Ryo Konno, Yusuke Kawashima, Makoto Arita, Shigeharu Ueki, Koichi Fukunaga   +16 more
wiley   +1 more source

Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials

Respiratory Research, 2021
Background Severe asthma is associated with a broad range of phenotypes and clinical characteristics. This analysis assessed whether select baseline patient characteristics could prognosticate mepolizumab efficacy in severe eosinophilic asthma.
Catherine Lemiere, Camille Taillé, Jason Kihyuk Lee, Steven G. Smith, Stephen Mallett, Frank C. Albers, Eric S. Bradford, Steven W. Yancey, Mark C. Liu   +8 more
doaj   +1 more source

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty [PDF]

, 2017
Francesco Menzella,1 Carla Galeone,1 Mirco Lusuardi,2 Anna Simonazzi,1 Claudia Castagnetti,1 Patrizia Ruggiero,1 Nicola Facciolongo1 1Department of Medical Specialties, Pneumology Unit, Arcispedale Santa Maria Nuova – IRCCS, Azienda USL di Reggio ...
Galeone C, Simonazzi A, Castagnetti C, Ruggiero P, Menzella F, Facciolongo N, Lusuardi M   +6 more
core  

Is Asthma Remission a New Achievable Goal? A Review of the Current Drug‐Related Evidence and Predictors

Allergy, EarlyView.
ABSTRACT Advances in asthma therapies have shown that clinical remission may be an achievable therapeutic goal for patients with asthma. This review discusses the current definitions of remission in asthma, the predictors of remission, airway inflammation/epithelial damage in asthma remission, airway remodeling, paradigms in defining remission and ...
Fatma Esra Gunaydin, Giulia Marcassa, Bianca Olivieri, Gianenrico Senna, Marco Caminati   +4 more
wiley   +1 more source

Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma

Качественная клиническая практика, 2019
Objective. To determine the clinical and economic consequences of the drug mepolizumab in patients with severe bronchial asthma (SBA) and the ineff ectiveness of omalizumab. Methods.
A. G. Tolkushin, V. A. Rogov, D. A. Ivanov, N. L. Pogudina   +3 more
doaj   +1 more source

Efficacy and Safety of Dupilumab in Chinese Adult Patients With Chronic Rhinosinusitis With Nasal Polyps: A Randomized, Placebo‐Controlled, Phase III Trial

Allergy, EarlyView.
Dupilumab significantly improved nasal polyp score, nasal congestion, olfaction, total symptom score, and disease‐specific quality of life in Chinese patients with uncontrolled CRSwNP. Incidence of treatment‐emergent adverse events was similar between dupilumab and placebo.
Mu Xian, Menglin Wang, Changqing Zhao, Lijia Wan, Yu Xu, Juan Meng, Rui Xu, Xicheng Song, Li Shi, Yucheng Yang, Yan Jiang, Yanzhen Wu, Bethany Ling, Vivian Li, Andrew P. Fontenot, Lacey R. Robinson, Neelam A. Phadke, Chengshuo Wang, Luo Zhang   +18 more
wiley   +1 more source

Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma [PDF]

Jared Silver,1 Andrea Steffens,2 Benjamin Chastek,2 Arijita Deb3 1Medical Affairs, GSK, Durham, NC, USA; 2Optum, Eden Prairie, MN, USA; 3Value, Evidence and Outcomes, GSK, Upper Providence, PA, USACorrespondence: Arijita Deb, Value, Evidence and Outcomes,
Steffens A, Chastek B, Silver J, Deb A
core   +1 more source